This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe Spring
THE SPRINGTIME PARTNERING EVENT
March 18–20, 2024 | Barcelona, SpainMarch 26–27, 2024 | Digital Partnering

Avanzanite Bioscience

Profile

Avanzanite Bioscience is a European-focused commercial-stage pharmaceutical company with a mission to accelerate patient access to ultra orphan or otherwise niche drugs for everyone in Europe, when nobody else dares to commercialise these products.
Derived from the word 'Tanzanite' - one of the rarest gemstones on earth - Avanzanite was formed to capitalize on two primary objectives, one economic, and one humanitarian. The economic goal is to offer end-to-end commercialization and distribution partnership with research-based biopharmaceutical originators to unlock the full value of their orphan medicines in European markets; this is the unique expertise and core competency of the Avanzanite team through its decades of operating experience navigating this area. Equally important, the Company's humanitarian goal stems from our commitment to enabling access to novel medicines for patients who suffer from orphan diseases regardless of where they live in Europe.
We offer end-to-end commercialization and distribution partnerships with research-based biopharmaceutical originators to unlock the full value of their orphan medicines in European markets. Many of these biotechs develop breakthrough Orphan Drugs, however they often do not reach patients in need which is a shame and unfair. At Avanzanite, we believe patients with Rare Diseases should have access to the latest medical innovations regardless of where they live. Avanzanite's founding mission is to tackle these critical issues in the European orphan drug space with our unique business model.